These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23936497)

  • 41. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
    Husa P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Urbanek P
    Eur J Gastroenterol Hepatol; 2011 May; 23(5):375-81. PubMed ID: 21502923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
    Morgan TR; Ghany MG; Kim HY; Snow KK; Shiffman ML; De Santo JL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Dienstag JL; Morishima C; Lindsay KL; Lok AS;
    Hepatology; 2010 Sep; 52(3):833-44. PubMed ID: 20564351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
    Giannini EG; Afdhal NH; Sigal SH; Muir AJ; Reddy KR; Vijayaraghavan S; Elkashab M; Romero-Gómez M; Dusheiko GM; Iyengar M; Vasey SY; Campbell FM; Theodore D
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1301-8. PubMed ID: 25777337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
    Méndez-Navarro J; Chirino RA; Corey KE; Gorospe EC; Zheng H; Morán S; Juarez JA; Chung RT; Dehesa-Violante M
    Dig Dis Sci; 2010 Sep; 55(9):2629-35. PubMed ID: 19960257
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
    Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
    Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
    Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
    Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
    Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.
    Jun BG; Park EJ; Lee WC; Jang JY; Jeong SW; Kim YD; Cheon GJ; Cho YS; Lee SH; Kim HS; Lee YN; Kim SG; Kim YS; Kim BS
    Korean J Intern Med; 2019 Sep; 34(5):989-997. PubMed ID: 29529840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.
    Freedman ND; Curto TM; Lindsay KL; Wright EC; Sinha R; Everhart JE;
    Gastroenterology; 2011 Jun; 140(7):1961-9. PubMed ID: 21376050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
    Bruno S; Sewpaul P; Russo ML; Boccaccio V; Almasio PL; Giannini EG
    Dig Liver Dis; 2015 Oct; 47(10):864-8. PubMed ID: 26187555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.
    Al Ashgar H; Helmy A; Khan MQ; Al Kahtani K; Al Quaiz M; Rezeig M; Kagevi I; Alshehri A; Al Kalbani A; Al Swat K; Dahab S; Elkum N; Al Fadda M
    Ann Saudi Med; 2009; 29(1):4-14. PubMed ID: 19139619
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.
    Martín-Carbonero L; Tuma P; Vispo E; Medrano J; Labarga P; González-Lahoz J; Barreiro P; Soriano V
    J Viral Hepat; 2011 Aug; 18(8):542-8. PubMed ID: 20819149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.